Gut Microbiota Market - Top Companies and Manufacturers

  • Report ID: 3251
  • Published Date: Jun 13, 2024
  • Report Format: PDF, PPT

Companies Dominating the Gut Microbiota Landscape

top-features-companies
    • Merck KGaA
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Metabiomics Corporation
    • ViThera Pharmaceuticals, Inc.
    • Second Genome Inc.
    • Microbiome Therapeutics LLC
    • Vedanta Biosciences, Inc.
    • Osel, Inc.
    • Synthetic Biologics, Inc.
    • Synlogic
    • 4D Pharma plc
    • Metabogen AB
    • Symbiotix Biotherapies, Inc.

Browse Key Market Insights with Data Illustration:

In the News

  • Merck KGaA a leading science and technology company and leader in genome editing, collaborated with Washington University in St. Louis, Missouri, USA, for leading towards the optimization of nutritional supplements to restore a healthy gut microbial community (microbiome). This gut bacteria research would use Merck’s genome-editing technology and may lead to diagnostics, and treatment for malnourished children.

  • Metabiomics Corp., an early-stage molecular diagnostics company entered into a joint venture with Prescient Medicine Holdings, LLC, a company that operates in the Medical Devices industry to develop an innovative microbiome diagnostics platform. This platform will detect precancerous colon polyps and diagnose other types of gastrointestinal diseases including Crohn’s, colitis (IBD), and irritable bowel syndrome (IBS).


Author Credits:  Radhika Pawar


  • Report ID: 3251
  • Published Date: Jun 13, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of gut microbiota is evaluated at USD 731.6 Million.

The gut microbiota market size was over USD 646.7 Million in 2023 and is expected to exceed USD 5.14 Billion by the end of 2036, growing at over 19.3% CAGR during the forecast period i.e., between 2024-2036. The increasing focus on gut health and the immunity system post-pandemic as well as the rising prevalence of digestive illness coupled with chronic diseases are the major factors driving the market growth.

North America is projected to dominate 35% industry share by 2036, led by rising concern about digestive illnesses such as gastroesophageal reflux disease (GERD) as well as other lifestyle disorders

Merck KGaA, Metabiomics Corporation, ViThera Pharmaceuticals, Inc., Second Genome Inc., Microbiome Therapeutics LLC, Vedanta Biosciences, Inc., Osel, Inc., Synthetic Biologics, Inc., Synlogic, 4D Pharma plc, Metabogen AB, Symbiotix Biotherapies, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying